Is Revolution Medicines a Good Stock to Own?
Though it’s still quite early in the year, pharmaceutical startup…
Buy
79
DVAX Quote, Financials, Valuation and Earnings
Last price:
$15.63
Seasonality move
:
-4.48%
Day range:
$15.60 - $15.67
52-week range:
$9.20 - $15.73
Dividend yield:
0%
P/E ratio:
54.00x
P/S ratio:
6.53x
P/B ratio:
3.44x
Volume:
1.8M
Avg. volume:
4.2M
1-year change:
26.15%
Market cap:
$1.8B
Revenue:
$277.2M
EPS (TTM):
-$0.38
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
DVAX
Dynavax Technologies Corp.
|
$80.3M | $0.08 | 11.43% | 73.54% | $20.50 |
|
AGIO
Agios Pharmaceuticals, Inc.
|
$12.1M | -$1.95 | 80.51% | -20.76% | $36.75 |
|
EWTX
Edgewise Therapeutics, Inc.
|
-- | -$0.44 | -- | -6.04% | $38.17 |
|
FOLD
Amicus Therapeutics, Inc.
|
$179.8M | $0.16 | 20.08% | 234.42% | $14.83 |
|
HYPD
Hyperion DeFi, Inc.
|
$500K | -- | 1679.36% | -- | $5.88 |
|
MRK
Merck & Co., Inc.
|
$16.2B | $2.03 | 1.82% | -62.58% | $113.48 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
DVAX
Dynavax Technologies Corp.
|
$15.63 | $20.50 | $1.8B | 54.00x | $0.00 | 0% | 6.53x |
|
AGIO
Agios Pharmaceuticals, Inc.
|
$27.19 | $36.75 | $1.6B | 3.91x | $0.00 | 0% | 35.01x |
|
EWTX
Edgewise Therapeutics, Inc.
|
$27.39 | $38.17 | $2.9B | -- | $0.00 | 0% | -- |
|
FOLD
Amicus Therapeutics, Inc.
|
$14.33 | $14.83 | $4.4B | -- | $0.00 | 0% | 7.33x |
|
HYPD
Hyperion DeFi, Inc.
|
$3.26 | $5.88 | $26.4M | -- | $0.00 | 0% | 84.50x |
|
MRK
Merck & Co., Inc.
|
$108.83 | $113.48 | $270.1B | 14.40x | $0.85 | 3.01% | 4.29x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
DVAX
Dynavax Technologies Corp.
|
35.13% | -0.768 | 24.82% | 6.74x |
|
AGIO
Agios Pharmaceuticals, Inc.
|
3.35% | 2.263 | 1.9% | 12.81x |
|
EWTX
Edgewise Therapeutics, Inc.
|
0.74% | 0.924 | 0.24% | 26.03x |
|
FOLD
Amicus Therapeutics, Inc.
|
65.77% | -0.323 | 18.22% | 1.91x |
|
HYPD
Hyperion DeFi, Inc.
|
10.72% | 22.776 | 13.53% | 2.04x |
|
MRK
Merck & Co., Inc.
|
44.38% | -0.108 | 20.79% | 1.06x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
DVAX
Dynavax Technologies Corp.
|
$80.5M | $21.3M | -5.15% | -7.65% | 22.42% | $32.6M |
|
AGIO
Agios Pharmaceuticals, Inc.
|
$9.8M | -$116.9M | -26.57% | -27.53% | -907.37% | -$89.7M |
|
EWTX
Edgewise Therapeutics, Inc.
|
-$570K | -$46.9M | -30.86% | -31.13% | -- | -$34.9M |
|
FOLD
Amicus Therapeutics, Inc.
|
$147.7M | $34.3M | -2.18% | -7.02% | 20.27% | $35.3M |
|
HYPD
Hyperion DeFi, Inc.
|
$302.5K | -$2.7M | -90.16% | -143.24% | -881.16% | -$2.8M |
|
MRK
Merck & Co., Inc.
|
$13B | $7.5B | 22.23% | 39.63% | 43.43% | $6.8B |
Dynavax Technologies Corp. vs. Competitors
-
Which has Higher Returns DVAX or AGIO?
Agios Pharmaceuticals, Inc. has a net margin of 28.38% compared to Dynavax Technologies Corp.'s net margin of -803.05%. Dynavax Technologies Corp.'s return on equity of -7.65% beat Agios Pharmaceuticals, Inc.'s return on equity of -27.53%.
Company Gross Margin Earnings Per Share Invested Capital DVAXDynavax Technologies Corp.84.82% $0.21 $823.4M AGIOAgios Pharmaceuticals, Inc.76.3% -$1.78 $1.3B -
What do Analysts Say About DVAX or AGIO?
Dynavax Technologies Corp. has a consensus price target of $20.50, signalling upside risk potential of 40.76%. On the other hand Agios Pharmaceuticals, Inc. has an analysts' consensus of $36.75 which suggests that it could grow by 35.16%. Given that Dynavax Technologies Corp. has higher upside potential than Agios Pharmaceuticals, Inc., analysts believe Dynavax Technologies Corp. is more attractive than Agios Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings DVAXDynavax Technologies Corp.1 1 1 AGIOAgios Pharmaceuticals, Inc.7 3 0 -
Is DVAX or AGIO More Risky?
Dynavax Technologies Corp. has a beta of 0.891, which suggesting that the stock is 10.879% less volatile than S&P 500. In comparison Agios Pharmaceuticals, Inc. has a beta of 0.894, suggesting its less volatile than the S&P 500 by 10.585%.
-
Which is a Better Dividend Stock DVAX or AGIO?
Dynavax Technologies Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Agios Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Dynavax Technologies Corp. pays -- of its earnings as a dividend. Agios Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DVAX or AGIO?
Dynavax Technologies Corp. quarterly revenues are $94.9M, which are larger than Agios Pharmaceuticals, Inc. quarterly revenues of $12.9M. Dynavax Technologies Corp.'s net income of $26.9M is higher than Agios Pharmaceuticals, Inc.'s net income of -$103.4M. Notably, Dynavax Technologies Corp.'s price-to-earnings ratio is 54.00x while Agios Pharmaceuticals, Inc.'s PE ratio is 3.91x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dynavax Technologies Corp. is 6.53x versus 35.01x for Agios Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DVAXDynavax Technologies Corp.6.53x 54.00x $94.9M $26.9M AGIOAgios Pharmaceuticals, Inc.35.01x 3.91x $12.9M -$103.4M
-
Which has Higher Returns DVAX or EWTX?
Edgewise Therapeutics, Inc. has a net margin of 28.38% compared to Dynavax Technologies Corp.'s net margin of --. Dynavax Technologies Corp.'s return on equity of -7.65% beat Edgewise Therapeutics, Inc.'s return on equity of -31.13%.
Company Gross Margin Earnings Per Share Invested Capital DVAXDynavax Technologies Corp.84.82% $0.21 $823.4M EWTXEdgewise Therapeutics, Inc.-- -$0.39 $562.8M -
What do Analysts Say About DVAX or EWTX?
Dynavax Technologies Corp. has a consensus price target of $20.50, signalling upside risk potential of 40.76%. On the other hand Edgewise Therapeutics, Inc. has an analysts' consensus of $38.17 which suggests that it could grow by 39.35%. Given that Dynavax Technologies Corp. has higher upside potential than Edgewise Therapeutics, Inc., analysts believe Dynavax Technologies Corp. is more attractive than Edgewise Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings DVAXDynavax Technologies Corp.1 1 1 EWTXEdgewise Therapeutics, Inc.7 2 0 -
Is DVAX or EWTX More Risky?
Dynavax Technologies Corp. has a beta of 0.891, which suggesting that the stock is 10.879% less volatile than S&P 500. In comparison Edgewise Therapeutics, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock DVAX or EWTX?
Dynavax Technologies Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Edgewise Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Dynavax Technologies Corp. pays -- of its earnings as a dividend. Edgewise Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DVAX or EWTX?
Dynavax Technologies Corp. quarterly revenues are $94.9M, which are larger than Edgewise Therapeutics, Inc. quarterly revenues of --. Dynavax Technologies Corp.'s net income of $26.9M is higher than Edgewise Therapeutics, Inc.'s net income of -$40.7M. Notably, Dynavax Technologies Corp.'s price-to-earnings ratio is 54.00x while Edgewise Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dynavax Technologies Corp. is 6.53x versus -- for Edgewise Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DVAXDynavax Technologies Corp.6.53x 54.00x $94.9M $26.9M EWTXEdgewise Therapeutics, Inc.-- -- -- -$40.7M
-
Which has Higher Returns DVAX or FOLD?
Amicus Therapeutics, Inc. has a net margin of 28.38% compared to Dynavax Technologies Corp.'s net margin of 10.24%. Dynavax Technologies Corp.'s return on equity of -7.65% beat Amicus Therapeutics, Inc.'s return on equity of -7.02%.
Company Gross Margin Earnings Per Share Invested Capital DVAXDynavax Technologies Corp.84.82% $0.21 $823.4M FOLDAmicus Therapeutics, Inc.87.38% $0.06 $673.2M -
What do Analysts Say About DVAX or FOLD?
Dynavax Technologies Corp. has a consensus price target of $20.50, signalling upside risk potential of 40.76%. On the other hand Amicus Therapeutics, Inc. has an analysts' consensus of $14.83 which suggests that it could grow by 3.51%. Given that Dynavax Technologies Corp. has higher upside potential than Amicus Therapeutics, Inc., analysts believe Dynavax Technologies Corp. is more attractive than Amicus Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings DVAXDynavax Technologies Corp.1 1 1 FOLDAmicus Therapeutics, Inc.2 5 0 -
Is DVAX or FOLD More Risky?
Dynavax Technologies Corp. has a beta of 0.891, which suggesting that the stock is 10.879% less volatile than S&P 500. In comparison Amicus Therapeutics, Inc. has a beta of 0.417, suggesting its less volatile than the S&P 500 by 58.311%.
-
Which is a Better Dividend Stock DVAX or FOLD?
Dynavax Technologies Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amicus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Dynavax Technologies Corp. pays -- of its earnings as a dividend. Amicus Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DVAX or FOLD?
Dynavax Technologies Corp. quarterly revenues are $94.9M, which are smaller than Amicus Therapeutics, Inc. quarterly revenues of $169.1M. Dynavax Technologies Corp.'s net income of $26.9M is higher than Amicus Therapeutics, Inc.'s net income of $17.3M. Notably, Dynavax Technologies Corp.'s price-to-earnings ratio is 54.00x while Amicus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dynavax Technologies Corp. is 6.53x versus 7.33x for Amicus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DVAXDynavax Technologies Corp.6.53x 54.00x $94.9M $26.9M FOLDAmicus Therapeutics, Inc.7.33x -- $169.1M $17.3M
-
Which has Higher Returns DVAX or HYPD?
Hyperion DeFi, Inc. has a net margin of 28.38% compared to Dynavax Technologies Corp.'s net margin of --. Dynavax Technologies Corp.'s return on equity of -7.65% beat Hyperion DeFi, Inc.'s return on equity of -143.24%.
Company Gross Margin Earnings Per Share Invested Capital DVAXDynavax Technologies Corp.84.82% $0.21 $823.4M HYPDHyperion DeFi, Inc.-- $0.05 $79.2M -
What do Analysts Say About DVAX or HYPD?
Dynavax Technologies Corp. has a consensus price target of $20.50, signalling upside risk potential of 40.76%. On the other hand Hyperion DeFi, Inc. has an analysts' consensus of $5.88 which suggests that it could grow by 80.22%. Given that Hyperion DeFi, Inc. has higher upside potential than Dynavax Technologies Corp., analysts believe Hyperion DeFi, Inc. is more attractive than Dynavax Technologies Corp..
Company Buy Ratings Hold Ratings Sell Ratings DVAXDynavax Technologies Corp.1 1 1 HYPDHyperion DeFi, Inc.2 0 0 -
Is DVAX or HYPD More Risky?
Dynavax Technologies Corp. has a beta of 0.891, which suggesting that the stock is 10.879% less volatile than S&P 500. In comparison Hyperion DeFi, Inc. has a beta of 2.689, suggesting its more volatile than the S&P 500 by 168.937%.
-
Which is a Better Dividend Stock DVAX or HYPD?
Dynavax Technologies Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Hyperion DeFi, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Dynavax Technologies Corp. pays -- of its earnings as a dividend. Hyperion DeFi, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DVAX or HYPD?
Dynavax Technologies Corp. quarterly revenues are $94.9M, which are larger than Hyperion DeFi, Inc. quarterly revenues of $302.5K. Dynavax Technologies Corp.'s net income of $26.9M is higher than Hyperion DeFi, Inc.'s net income of $6.6M. Notably, Dynavax Technologies Corp.'s price-to-earnings ratio is 54.00x while Hyperion DeFi, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dynavax Technologies Corp. is 6.53x versus 84.50x for Hyperion DeFi, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DVAXDynavax Technologies Corp.6.53x 54.00x $94.9M $26.9M HYPDHyperion DeFi, Inc.84.50x -- $302.5K $6.6M
-
Which has Higher Returns DVAX or MRK?
Merck & Co., Inc. has a net margin of 28.38% compared to Dynavax Technologies Corp.'s net margin of 33.68%. Dynavax Technologies Corp.'s return on equity of -7.65% beat Merck & Co., Inc.'s return on equity of 39.63%.
Company Gross Margin Earnings Per Share Invested Capital DVAXDynavax Technologies Corp.84.82% $0.21 $823.4M MRKMerck & Co., Inc.75.59% $2.32 $93.3B -
What do Analysts Say About DVAX or MRK?
Dynavax Technologies Corp. has a consensus price target of $20.50, signalling upside risk potential of 40.76%. On the other hand Merck & Co., Inc. has an analysts' consensus of $113.48 which suggests that it could grow by 4.27%. Given that Dynavax Technologies Corp. has higher upside potential than Merck & Co., Inc., analysts believe Dynavax Technologies Corp. is more attractive than Merck & Co., Inc..
Company Buy Ratings Hold Ratings Sell Ratings DVAXDynavax Technologies Corp.1 1 1 MRKMerck & Co., Inc.15 12 0 -
Is DVAX or MRK More Risky?
Dynavax Technologies Corp. has a beta of 0.891, which suggesting that the stock is 10.879% less volatile than S&P 500. In comparison Merck & Co., Inc. has a beta of 0.291, suggesting its less volatile than the S&P 500 by 70.859%.
-
Which is a Better Dividend Stock DVAX or MRK?
Dynavax Technologies Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & Co., Inc. offers a yield of 3.01% to investors and pays a quarterly dividend of $0.85 per share. Dynavax Technologies Corp. pays -- of its earnings as a dividend. Merck & Co., Inc. pays out 46.32% of its earnings as a dividend. Merck & Co., Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios DVAX or MRK?
Dynavax Technologies Corp. quarterly revenues are $94.9M, which are smaller than Merck & Co., Inc. quarterly revenues of $17.2B. Dynavax Technologies Corp.'s net income of $26.9M is lower than Merck & Co., Inc.'s net income of $5.8B. Notably, Dynavax Technologies Corp.'s price-to-earnings ratio is 54.00x while Merck & Co., Inc.'s PE ratio is 14.40x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dynavax Technologies Corp. is 6.53x versus 4.29x for Merck & Co., Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DVAXDynavax Technologies Corp.6.53x 54.00x $94.9M $26.9M MRKMerck & Co., Inc.4.29x 14.40x $17.2B $5.8B
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Has Vistra Stock Gone Up?
Integrated power generation business Vistra (NYSE:VST) surprised investors recently when…
Why Is Amkor Stock Up So Much?
Semiconductor packaging and testing major Amkor (NASDAQ:AMKR) has started 2026…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Sell
48
Is GOOGL Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Alerts
Buy
75
AGX alert for Jan 17
Argan, Inc. [AGX] is up 16.4% over the past day.
Buy
80
ASTS alert for Jan 17
AST Spacemobile, Inc. [ASTS] is up 14.32% over the past day.
Buy
84
IREN alert for Jan 17
IREN Ltd. [IREN] is up 11.35% over the past day.
